September 22, 2007 -- Benda Pharmaceutical announced the appointment of a third independent board member. With three outside board members, Benda’s board is now “independent” under Nasdaq rules and qualifies Benda to apply for listing on the Nasdaq exchange. Lilly reported its first-half revenues in China were up 26% from the year earlier; Genentech partnered with a new Taiwanese company on a drug for HIV/AIDS; Sinobiomed reported success in a Phase IIa trial of rBAT, its recombinant batroxobin product; Shanghai Century announced earnings for the Chinese company it is expecting to acquire: Kelun Pharmaceutical; 3SBio benefitted when an analyst predicted the company’s profits would quadruple; and, finally, Sanofi-Aventis announced it would take its long-running patent fight against Jiangsu Hengrui to a higher court. More details...
